The Company has Referred Buxton and its CEO, Alexander Erwin Parker, to Federal and State Authorities for Consideration of Criminal Prosecution The Company Stands Firmly Behind its Financial Statements and Accounting Judgments LOS ANGELES, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Daily Journal Corporation (the “Company”) today issued the following statement in response to a flood of false, misleading and self-interested correspondence from Buxton Helmsley USA, Inc. (“BuHeUI”) and its Chief Executive Officer, Alexa ...

Core Viewpoint - Neuphoria Therapeutics Inc. is urging shareholders to vote for its director nominees on the WHITE proxy card, following a recommendation from Institutional Shareholders Services (ISS) that supports the company's management against a proxy contest initiated by Lynx1 Capital Management [1][2][3] Group 1: Company Overview - Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for neuropsychiatric disorders [7] - The company is advancing its lead drug candidate, BNC210, which is designed to treat post-traumatic stress disorder (PTSD) and is characterized as a first-of-its-kind anti-anxiety therapeutic [7] - Following the Phase 3 clinical trial results announced on October 20, 2025, which missed primary and secondary endpoints, Neuphoria has halted development of BNC210 for social anxiety disorder and is conducting a strategic review [7] Group 2: Proxy Contest and ISS Recommendation - ISS has recommended that Neuphoria shareholders vote FOR both of the company's director nominees, Peter Miles Davies and David Wilson, and WITHHOLD votes for the dissident nominees from Lynx1 Capital Management [2][3] - The ISS report highlighted that the dissident has not presented a compelling case for change, thus supporting the management's nominees [3] - Neuphoria's board has been proactive in raising capital ahead of the Phase 3 trial data readout, strengthening the company's balance sheet as it proceeds with a strategic review [6]

Core Viewpoint - Neuphoria Therapeutics Inc. urges shareholders to vote for its director nominees as recommended by Institutional Shareholders Services (ISS), emphasizing the board's proactive actions and strategic review process to maximize shareholder value [1][2][3]. Company Overview - Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for neuropsychiatric disorders, with its lead drug candidate BNC210 aimed at treating post-traumatic stress disorder (PTSD) [7]. - The company has halted the development of BNC210 for social anxiety disorder following a Phase 3 clinical trial that missed its primary and secondary endpoints [7]. Proxy Contest - ISS has recommended that shareholders vote for Neuphoria's director nominees, Peter Miles Davies and David Wilson, while withholding votes for the dissident nominees from Lynx1 Capital Management [1][3]. - The board's actions in response to the clinical trial results and the dissident's offer have been deemed appropriate, with a commitment to transparency and shareholder updates [6]. Strategic Review - Neuphoria's board is conducting a strategic review to explore alternatives that could provide maximum value to shareholders, which includes inviting the dissident to participate under similar terms as other parties [6]. - The company has raised capital proactively ahead of the Phase 3 trial data readout, strengthening its balance sheet for the ongoing strategic review [6].

Core Viewpoint - Neuphoria Therapeutics Inc. is addressing what it perceives as a deceptive campaign by Lynx1 Master Fund LP aimed at distracting shareholders from Lynx1's own shortcomings and lack of a clear plan [1][2][3] Company Positioning - Neuphoria emphasizes its commitment to transparency and value creation, urging stockholders to support its nominees while withholding votes for Lynx1's nominees [2][8] - The company is focused on developing therapies for neuropsychiatric disorders, with its lead drug candidate BNC210 targeting PTSD [9] Response to Lynx1's Claims - Neuphoria refutes Lynx1's assertions, presenting a detailed counterargument to each claim made by Lynx1, highlighting the company's strategic actions and board qualifications [4][5][6][7] - The company asserts that Lynx1's nominees lack the necessary experience and understanding of the company's needs, particularly in neuropsychiatric disorders [5][7] Strategic Review and Clinical Trials - Following the AFFIRM-1 Phase 3 clinical trial results, which missed primary and secondary endpoints, Neuphoria has halted development of BNC210 for social anxiety disorder and is conducting a strategic review [9] - The company is also engaged in partnerships, including one with Merck, to advance its pipeline for treating cognitive deficits in Alzheimer's disease [9] Board Composition and Governance - Neuphoria defends its current board's qualifications and experience, contrasting them with Lynx1's nominees, who are portrayed as lacking relevant expertise [6][7] - The company emphasizes the importance of having a strong cash balance and strategic oversight in navigating its clinical trials and corporate governance [6][7]

Core Viewpoint - Knighted Pastures has withdrawn its nominations for the Board of Allied Gaming due to a court ruling that prevents changes to the Board's composition, which has made continuing the proxy contest unfeasible [1][2]. Group 1: Legal Developments - The United States District Court for the Central District of California issued a preliminary injunction that halts the election of six directors to Allied Gaming's Board, based on claims that Knighted Pastures is part of an undisclosed group with other shareholders [1]. - Knighted Pastures has appealed the District Court Order but has decided to abandon the proxy contest due to the high costs associated with the lawsuit and the delay in holding a shareholder vote [2]. Group 2: Company Actions and Statements - Knighted Pastures has donated its shares to multiple charities as part of its decision to step back from its investment in Allied Gaming [2]. - The Managing Member of Knighted Pastures, Roy Choi, stated that the company has previously succeeded in two lawsuits that preserved shareholder value by preventing Allied Gaming from executing unfair share issuances [2].

Core Viewpoint - Brookdale Senior Living Inc. is urging shareholders to vote for its nominated directors, emphasizing that the current board's strategy is effectively driving shareholder value and operational momentum [1][3][11]. Financial Performance - In June, Brookdale achieved an 81.1% same community weighted average occupancy, with a month-end occupancy of 82.8%, indicating strong demand and sales execution [2]. - The second quarter weighted average consolidated occupancy was 80.1%, marking a significant milestone for cash flow growth [2]. - Since 2022, Brookdale has renegotiated leases for approximately 250 communities and reduced the number of leased units by 19% since Q1 2021, with plans to decrease its community portfolio to less than 600 by year-end 2025 from over 1,000 in 2017 [7]. Board Composition and Strategy - Brookdale's board consists of eight highly qualified directors, seven of whom are independent, with an average tenure of less than four years, ensuring a mix of skills critical for the company's growth [5][4]. - The board is actively engaged in a CEO search process, supported by an independent search firm, to find a candidate with the necessary experience in senior living, healthcare, hospitality, and real estate [6]. Shareholder Engagement - The company has made efforts to engage with Ortelius Advisors to avoid a proxy contest, but Ortelius has not engaged constructively [10]. - Brookdale emphasizes the importance of every shareholder vote and urges them to disregard any opposing proxy cards from Ortelius [12][11]. Competitive Positioning - Brookdale's operational improvements and strategic initiatives have positioned it to outperform peers in key metrics such as consolidated RevPAR, operating income per available unit, and adjusted EBITDA margin compared to 2019 [7]. - The company highlights that Ortelius lacks understanding of its business model and has proposed a flawed plan that could jeopardize Brookdale's progress [3][8].

Core Viewpoint - Oportun is committed to reaching a constructive compromise with Findell Capital Management and has made multiple proposals to change the Board's composition, which Findell has not responded to [1][3] Group 1: Board Actions - The Board has decided to reduce the number of directors and rebalance the skills and experience of its members, reflecting stockholder feedback [2] - The decision includes not nominating incumbent Lead Independent Director Neil Williams and director Scott Parker, both of whom are former Chief Financial Officers [2] Group 2: Company Overview - Oportun is a mission-driven financial services company that has provided over $20.3 billion in responsible credit and saved its members more than $2.4 billion in interest and fees since its inception [3] - The company empowers its members to build a better financial future by offering intelligent borrowing, savings, and budgeting capabilities, helping them set aside an average of over $1,800 annually [3]

Core Viewpoint - Brookdale Senior Living Inc. supports the recommendation from Institutional Shareholder Services (ISS) against granting control of the Board of Directors to Ortelius, emphasizing the lack of a clear performance assessment and feasibility details in Ortelius' plan [1][2]. Group 1: Board Composition and Expertise - Brookdale urges shareholders to vote for all eight of its highly qualified director nominees, highlighting the critical skillsets of directors Lee Wielansky and Victoria Freed, which are essential for the company's strategic direction and operational efficiency [1][2][10]. - The company argues that replacing Wielansky or Freed with Ortelius' nominees would deprive the Board of necessary expertise and institutional knowledge, potentially impairing the recruitment of a new CEO and jeopardizing shareholder value [2][9]. - Wielansky's extensive operational experience in real estate and his leadership in optimizing Brookdale's portfolio are presented as vital for the company's ongoing strategy [4][6]. Group 2: Critique of Ortelius' Candidates - Ortelius candidate Lori Wittman has limited experience in senior living, primarily focused on financial management in REITs, which does not align with Brookdale's operational needs [3]. - Ortelius candidate Steven Vick has not held significant leadership roles in over two decades, raising concerns about his qualifications and experience relevant to Brookdale's scale and operations [7]. - The company emphasizes that the current Board's composition, including experienced directors, is crucial for effective oversight and support during a pivotal time for the company [9]. Group 3: Strategic Direction and Shareholder Value - Brookdale's Board has intentionally refreshed its composition to balance tenure and skillsets, ensuring that the company can effectively navigate its strategic priorities and enhance shareholder value [10][11]. - The company asserts that its eight director nominees collectively possess the right mix of expertise necessary for continued financial and operational performance [10].

Core Viewpoint - Barnwell Industries, Inc. is focused on moving forward without distractions to drive value for all shareholders amidst a proxy contest initiated by Ned Sherwood and his affiliated entities [1]. Group 1: Proxy Contest Developments - Glass Lewis & Co., a leading independent proxy advisory firm, has deemed the removal of Barnwell's incumbent director nominees as unwarranted, supporting the current Board's track record and strategic direction [2]. - The Board emphasizes its commitment to avoiding prolonged conflict and unnecessary costs, expressing openness to constructive discussions with Mr. Sherwood to seek an amicable resolution [3]. Group 2: Company Strategy and Performance - Barnwell is executing a clear strategy aimed at driving value, improving performance, and maintaining the trust of long-term stockholders [4]. - The company remains committed to responsible stewardship and aims to avoid wasteful disputes while seeking productive resolutions [3]. Group 3: Company Overview - Barnwell Industries, Inc. and its subsidiaries are primarily engaged in oil and natural gas exploration and development [5].